Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation

“…Long-term safety—24 months—of the same doses of ozanimod was evaluated in an independent phase II clinical trial, RADIANCE (safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis). Consistently, the safety profile of the compound was confirmed in the long term, and similar results on brain volume loss have been observed [ 154 ]. Despite the similarity with siponimod, the safer profile of this therapeutic agent made ozanimod suitable for further investigations.…”

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis

“…Fingolimod and siponimod have been approved for treatment of relapsing forms of multiple sclerosis. [16][17][18][19][20] Other S1P receptor modulators are in clinical development as potential therapies, including ozanimod in multiple sclerosis and UC, [21][22][23] ponesimod in multiple sclerosis and psoriasis, 24,25 and amiselimod in multiple sclerosis and Crohn's disease. [26][27][28] Fingolimod, a first-generation S1P receptor modulator, interacts nonselectively with S1P isoforms 1 through 5.…”

Resolution of inflammation: from basic concepts to clinical application

“…This drug prevents lymphocyte homing to the inflamed mucosa with subsequent immune cell activation and retention. Finally, S1P1 receptor agonists (e.g., ozanimod) have been shown to control immune cell efflux from lymph nodes and have been tested in multiple sclerosis [78][79][80]. Collectively, these findings suggest that selective immune cell intervention may block proinflammatory immune processes and foster resolution of inflammation.…”